“What has emerged from these initial discoveries is one of the most fascinating stories in modern neuroscience…
“Cannabis-like compounds offer therapeutic potential for the treatment of breast, prostate and bone cancer in patients.”
~British Journal of Pharmacology, 2011
—————————————————————————————————————————————–
“The literature is nearly unanimous in suggesting that cannabinoids and endocannabinoids reduce the progression of cancer in preclinical model systems.”
Cancer and Metastasis Review in October 2011.
THC and CBD may slow down or stop the growth of cancer cells in brain, lung, breast, liver and skin.
Since 2001, researched has been suggesting a correlation between cannabinoid receptors and glioblastoma, an aggressive brain cancer.
The human cannabinoid anandamide was shown to inhibit growth of malignant melanoma cells in 2013.
A connection between Hodgkin’s Lymphoma cells and cannabinoid receptors was found in 2013.
Cannabinoid receptors have been isolated in certain types of ovarian and prostate tumors.
In pancreatic tumors, higher volumes of cannabinoid receptors were shown in patients with shorter survival time (median 6 months).
Breast cancer cells were found to contain cannabinoid receptors in 2006.
The level of cannabinoid receptors in Stage IV colorectal cancer were found to be a factor of bad prognosis following surgery.
It’s important to note that most of these results come from animal research. In some cases, however, human cancer cells were examined.
Concrete proof of how different kinds of cancer respond to specific compounds in cannabis extracts may be years away.
Still, our hopes can be buoyed by the incredible potential before us.
Copyright Notice ©CannabisFindings.com. 2018. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to CannabisFindings.com with appropriate and specific direction to the original content.
